These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24286361)

  • 1. Two faces of inflammation: an immunopharmacological view.
    Moilanen E
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):2-6. PubMed ID: 24286361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
    Harris SJ; Foster JG; Ward SG
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proximal signaling molecules as potential targets for anti-inflammatory therapy.
    Löwenberg M
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):560-4. PubMed ID: 17786854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs.
    Karin M
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii62-ii64. PubMed ID: 15479874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents.
    Naik SR; Wala SM
    Recent Pat Inflamm Allergy Drug Discov; 2013 Jan; 7(1):62-95. PubMed ID: 23140569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscarinic receptor agonists and antagonists: effects on inflammation and immunity.
    Verbout NG; Jacoby DB
    Handb Exp Pharmacol; 2012; (208):403-27. PubMed ID: 22222708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target.
    Kaminska B; Gozdz A; Zawadzka M; Ellert-Miklaszewska A; Lipko M
    Anat Rec (Hoboken); 2009 Dec; 292(12):1902-13. PubMed ID: 19943344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte lipid bodies regulation and function: contribution to allergy and host defense.
    Bozza PT; Melo RC; Bandeira-Melo C
    Pharmacol Ther; 2007 Jan; 113(1):30-49. PubMed ID: 16945418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
    Nishimoto N
    Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adipokines: some players of inflammation in inflammatory rheumatic diseases and systemic autoimmune diseases?].
    Toussirot E
    Presse Med; 2013 Jan; 42(1):13-8. PubMed ID: 22521967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-activated receptors as drug targets in inflammation and pain.
    Vergnolle N
    Pharmacol Ther; 2009 Sep; 123(3):292-309. PubMed ID: 19481569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA.
    Oliver E; McGillicuddy F; Phillips C; Toomey S; Roche HM
    Proc Nutr Soc; 2010 May; 69(2):232-43. PubMed ID: 20158940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases].
    Bessis N; Fradelizi D; Fournier C; Boissier MC
    C R Seances Soc Biol Fil; 1995; 189(4):579-90. PubMed ID: 8564571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition.
    Hua S; Cabot PJ
    Pain Physician; 2013; 16(3):E199-216. PubMed ID: 23703419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopharmacology: anti-inflammatory therapy targeting transcription factors.
    Pfeilschifter J; Mühl H
    Eur J Pharmacol; 1999 Jun; 375(1-3):237-45. PubMed ID: 10443580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
    Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Signaling mechanisms involved in resolution of inflammation].
    Cervantes-Villagrana RD; Cervantes-Villagrana AR; Presno-Bernal JM
    Gac Med Mex; 2014; 150(5):440-9. PubMed ID: 25275846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis.
    Little PJ; Chait A; Bobik A
    Pharmacol Ther; 2011 Sep; 131(3):255-68. PubMed ID: 21510977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.